Initial change of glycosaminoglycans in systemic scleroderma.
7 clinically uninvolved as well as 8 involved (6 moderately, 2 markedly) back or forearm skin specimens from 12 patients with systemic scleroderma were subjected to quantitative evaluation and to qualitative analysis of glycosaminoglycans (GAG) by one-dimensional and two-dimensional cellulose acetate electrophoresis. Skin specimens from the back, clinically uninvolved but histologically demonstrating the initial change, revealed increased amounts of hyaluronidase, chondroitinase-resistant GAG of varying electrophoretic mobilities, and one of them was chemically confirmed to be heparan sulfate variant, whereas involved skin specimens showed hardly this increase.
D000328:Adult; D003871:Dermatan Sulfate / Q000378:metabolism; D004588:Electrophoresis, Cellulose Acetate; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism*; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000378:metabolism* / Q000473:pathology; D012867:Skin / Q000378:metabolism / Q000473:pathology
D006025:Glycosaminoglycans; D003871:Dermatan Sulfate; D006820:Hyaluronic Acid